亚宝药业集团股份有限公司 关于签订中药新药项目技术转让协议的公告

Transaction Overview - The company signed a technology transfer agreement with Shanxi Traditional Chinese Medicine Research Institute on August 4, 2025, for the acquisition of a Class 1 new Chinese medicine "Chaiqin Ning Shen Granules" for RMB 22 million [2] - This transaction does not constitute a related party transaction and falls within the chairman's authorization scope, thus does not require board or shareholder approval [2] Counterparty Information - Shanxi Traditional Chinese Medicine Research Institute, established in 1957, is one of the earliest TCM research institutions in China, integrating medical care, research, teaching, and industry [3] - The institute has undertaken over 1,033 research projects and has received numerous awards, including 15 national new drug approvals and 31 authorized invention patents [3] Target Transaction Details - The transfer includes the clinical trial approval notice and related patents for "Chaiqin Ning Shen Granules" [4] - The granules are indicated for liver qi stagnation and anxiety-related insomnia, showing significant improvement in symptoms [5] Market Context - According to a report by the China Sleep Research Society, 48.5% of adults in China experience sleep difficulties, with a growing prevalence of insomnia-related anxiety [6] - The insomnia medication market in China grew from RMB 9.84 billion in 2016 to RMB 11.7 billion in 2020, with projections of RMB 15.12 billion and RMB 21.19 billion by 2025 and 2030, respectively [6] Agreement Details - The agreement stipulates that the company will pay a total of RMB 22 million, with payments tied to specific milestones in the drug development process [12] - The agreement includes provisions for the transfer of all relevant technical materials and responsibilities for both parties in the development process [8][9] Impact on the Company - The acquisition of the clinical trial approval and patent rights for "Chaiqin Ning Shen Granules" is expected to enhance the company's R&D pipeline for innovative Chinese medicines, improving its core competitiveness and sustainable development [16] - The agreement's implementation may take time, and it is not expected to have a significant short-term impact on the company's operating performance [16]